Bacteria May Be Used to Make Cancer Drugs
Posted on: Tuesday, 31 October 2006, 18:00 CST
British scientists are considering using bacteria to make anti-cancer drugs that are difficult to create synthetically in a lab.
The University of Warwick researchers say the bacterium Streptomyces coelicolor naturally produces antibiotics called prodiginines, which can target and kill cancer cells.
A synthetic prodiginine analogue called GX15-070 is currently in phase 1 and 2 cancer treatment trials. However, analogues of other prodiginines, such as streptorubin B, could be even more powerful anti-cancer tools, but they cannot currently be easily produced synthetically on a lab bench, the scientists said.
Professor Greg Challis and colleagues believe by manipulation of the enzyme content of the bacteria, they could produce a range of different compounds based closely on the form of streptorubin B normally formed by the bacteria.
Some of those analogues might provide the basis for developing new anti cancer drugs.
This approach combines the strengths of conventional organic synthesis, with the synthetic power of biology, to assemble complex and synthetically difficult structures, said Challis. It could be particularly valuable for generating analogues of streptorubin B with all the promise that holds for the development of new anti cancer drugs
The proposal appears in the journal Chemical Communications.
Source: United Press International
Related Articles
- Anti-Drug Group Fights Medical-Marijuana Bill
- Guatemala anti-drug chief arrested for smuggling
- Guatemalan Anti-drug Chief Caught Smuggling
- Susilo Calls on Localities to Set Up Anti-Drug Centers
- Czech Cabinet Approves 2005-2006 Anti-Drug Policy
- Chile, Colombia Agree to Intensify Anti-Drug Cooperation
- Dear Pharmacist: It's Not 'Anti-Drug' to Advocate Consumer Caution
- Cancer 'Wonder Drug' Brings New Hope for Women Treatment for Breast Disease Approved for Scots Patients
- Bush Anti-Drug Plan to Target Painkillers
- Bush Anti-Drug Plan to Target Pain Killers
User Comments (0)

RSS Feeds